EU Takes Lessons From Valsartan Crisis
Urges Close Examination Of Active Substance Manufacturing Processes
EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.
You may also be interested in...
Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.
The EMA is launching an initiative aimed at preventing impurities in medicines and better handling cases where impurities do occur, following the agency’s experiences in dealing with sartans that contained nitrosamine impurities.
Stada and Accord are among the companies affected by an EU wide recall of valsartan manufactured by a Chinese supplier.